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Mechanisms that prevent inappropriate or excessive
interleukin-17-producing T helper (Th17) cell re-
sponses after microbial infection may be necessary
to avoid autoimmunity. Here, we define a pathway
initiated by engagement of type I IFN receptor
(IFNAR) expressed by dendritic cells (DC) that culmi-
nated in suppression of Th17 cell differentiation.
IFNAR-dependent inhibition of an intracellular trans-
lational isoform of Osteopontin, termed Opn-i, dere-
pressed interleukin-27 (IL-27) secretion and pre-
vented efficient Th17 responses. Moreover, Opn-i
expression in DC and microglia regulated the type
and intensity of experimental autoimmune encepha-
lomyelitis (EAE). Mice containing DC deficient in
Opn-i produced excessive amounts of IL-27 and
developed a delayed disease characterized by an en-
hanced Th1 response compared with the dominant
Th17 response of Opn-sufficient mice. Definition of
the IFNAR-Opn-i axis that controls Th17 develop-
ment provides insight into regulation of Th cell sub-
lineage development and the molecular basis of type
I interferon therapy for MS and other autoimmune
diseases.
INTRODUCTION
Efficient protection against microbial infection depends on an in-
teraction between the innate and adaptive immune systems.
Recognition of microbial pathogens by pattern-recognition re-
ceptors expressed by dendritic cells (DC) activates these cells
to efficiently present pathogen-derived antigens to T cells, which
initiate adaptive immune responses. Whereas the task of CD8+ T
cells is limited primarily to lysis of cells that display peptides de-
rived from intracellular pathogens, themore complex activities of
CD4+ T cells are divided among several functionally distinct sub-
lineages of CD4+ T cells. T helper 1 (Th1) and T helper 2 (Th2)
cells, discovered some 20 years ago, have evolved to enhance
clearance of intracellular pathogens, including viruses and para-
sites, respectively. A recently defined third sublineage of Th cells68 Immunity 29, 68–78, July 18, 2008 ª2008 Elsevier Inc.termed Th17 cells may be equipped to protect against infection
by extracellular bacterial and fungal pathogens including Myco-
bacteria, Borrelia burgdorferi, and Candida albicans (Burchill
et al., 2003; Khader et al., 2007; Umemura et al., 2007). The
nature of the Th17 cell response reflects, in part, the ability of
its signature cytokine—interleukin-17 (IL-17)—to attract exten-
sive inflammatory cellular infiltrates through interactions with
chemokine receptors. Excessive Th17 cell responses after
infection with, for example, B. burgdorferi, can result in wide-
spread inflammatory tissue destruction and chronic autoimmune
disease.
These considerations suggest that mechanisms that prevent
inappropriate or excessive Th17 cell responses after microbial
infection may be essential to avoid host immunopathology and
associated autoimmunity. For example, DC may not produce
sufficient quantities of cytokines that promote Th17 cell develop-
ment unless particular infectious stimuli are present. A more
reliable mechanism for controlling Th17 cell responses depends
on active suppression of Th17 cell differentiation by antigen-
presenting DC that may selectively allow antiviral Th1 cell re-
sponses.
The ability of antigen-presenting DC to differentially regulate
generation of Th cell subsets is not well understood. Although re-
cent reports have indicated that dectin-1-Syk-CARD9 signaling,
triggered by detection of fungal b-glucans, in DC promotes Th17
cell responses (Leibundgut-Landmann et al., 2007), whether
activated DC inhibit Th17 cell responses has not been estab-
lished. We reasoned that because a molecular signature of viral
infection is early expression of type I interferons (IFN-I), engage-
ment of the IFN-I receptor (IFNAR) on antigen-presenting DC
might constitutively pre-empt the ability of these DC to promote
Th17 cell responses in the course of viral infections.
Here, we show that robust Th17 cell responses depended on
the ability of a newly defined translational intracellular isoform of
Osteopontin (Shinohara et al., 2008)—Opn-i—to inhibit DC-
dependent secretion of the potent inhibitory cytokine IL-27.
IFNAR-dependent inhibition of Opn-i expression resulted in
derepression of IL-27 secretion and inhibition of the Th17 cell
response in vitro and in vivo. Mice that contain Opn-i-deficient
DC developed increased serum IL-27 amounts and a dominant
pathogenic Th1 response in the spinal cord compared with the
central nervous system (CNS) infiltrates that developed in Opn
WT control mice. Definition of an IFNAR-Opn-i axis that regulates
the Th17 cell response provides insight into the therapeutic
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IFNAR-Dependent Inhibition of Th17 Cell Responsesimpact of IFN-I treatment of multiple sclerosis and other Th17
cell diseases (Paty et al., 1993; Yu et al., 1996) as well as a ratio-
nale for new approaches to identify IFNAR ligands with
increased therapeutic efficacy in MS and related diseases.
RESULTS
IFNAR Engagement Inhibits Opn-i-Dependent
Generation of Th17 Cells
Although some forms of microbial infection can efficiently stimu-
late robust Th17 cell responses, the Th17 cell response after
conventional immunization is normally meager compared to
the Th1 cell response (Park et al., 2005; Gocke et al., 2007).
We investigated whether Th1 cell dominance is imprinted by
DC at the outset of a polyclonal T cell response. In the absence
of T cell-polarizing reagents, cultures containing resting DC or
DC that had been preactivated with LPS contained >10-fold
greater numbers of IFN-g-producing CD4+ T cells compared
with IL-17 cell-producing cells (Figure 1A, top). Culture condi-
tions that contained rIL-23, IL-4, and IFN-g antibodies only mod-
estly increased the Th17 cell response. However, the Th17:Th1
cell ratio increased substantially in cultures containing T cells
and DC deficient in IFNAR (Figure 1A, bottom).
IFNAR Expression by DC Suppresses
the Th17 Cell Response
Expression of the IL-6 and TGF-b cytokines is necessary for gen-
eration of Th17 cells from naive T cell precursors (Veldhoen et al.,
2006; Bettelli et al., 2006), whereas IL-23 contributes to expan-
sion of this RORgt-dependent Th cell subset (Park et al., 2005;
Harrington et al., 2005; Ivanov et al., 2006) from activated or
memory T cells (reviewed in Kastelein et al., 2007). To test the
possibility that the above result reflected, in part, an increase
in memory Th17 cells in Ifnar1/ mice, we asked whether
IFNAR-deficient antigen-presenting DC alone could drive T cells
from IFNAR WT donors to differentiate into Th17 cells. To this
end, we compared the ability of Ifnar1/ DC or Ifnar1+/+ DC to
present MOG peptide to (Ifnar1+/+) CD4+ T cells expressing the
MOG-specific T cell receptor (2D2) transgene (Figure 1B). Inclu-
sion of Ifnar1/ DC altered the Th1 cell and Th17 cell balance in
favor of the latter (Figure 1B). Indeed, the Th17:Th1 cell ratios
were increased approximately 3- to 5-fold in cultures containing
Ifnar1/ DC, independent of its state of activation. Enhance-
ment of Th17 cell responses could not be attributed to IFNAR-
dependent changes in inhibitory Th1 cell and Th2 cell cytokines
(IFN-g, IL-4) or to IL-23, because these cultures included IL-4
and IFN-g antibodies and exogenous IL-23 (Figure 1B). IFNAR
expression by DC was also sufficient to fully inhibit the MOG-
specific Th17 cell response in the absence of Th17 cell-polariz-
ing conditions (Figure S1 available online). We also examined
Th17 cell expansion in cultures containing Ifnar1+/+ or Ifnar1/
T cells. Under both Th17 cell-neutral and Th17 cell-polarizing
culture conditions, with or without activation of DC by rIFN-a,
CpG, and LPS, cultures containing IFNAR-deficient T cells did
not display substantially enhanced Th17 cell responses (Figures
S2A and S2B).
We then tested the impact of Ifnar1/ DC on activation of
CD4+ T cells expressing an OVA-specific TCR transgene, OT-2,
in cultures containing IL-6, TGF-b, IL-23, and neutralizing IFN-gand IL-4 antibodies, i.e., under conditions engineered to fully op-
timize Th17 cell development from both naive and memory T cell
pools. Presentation of the OVA peptide by Ifnar1/ DC pro-
voked substantially enhanced Th17 cell responses compared
to cultures containing Ifnar1+/+ DC (Figure 1C), indicating that
supplementation of cultures with exogenous IL-6 and IL-23 or
inhibition of IFN-g and IL-4 does not enhance responses of
cultures containing Ifnar1+/+ DC to the degree seen in cultures
containing Ifnar1/ DC, i.e., increased Th17 responses pro-
moted by Ifnar1/ DC do not reflect enhanced production of
IL-6 or IL-23 or inhibition of IFN-g and IL-4.
DC used in the experiment were not activated, so autocrine
amounts of IFN-I, which are constitutively expressed by unstim-
ulated DC (Taniguchi and Takaoka, 2001), may be sufficient to
inhibit Th17 cell generation. Indeed, in the absence of exogenous
rIFN-a, cultures containing Ifnar1/ DC generated enhanced
Th17 cell responses even under nonpolarized conditions (Fig-
ure 1D). We further examined the impact of increasing concen-
trations of IFN-a on the Th17 cell response of CD4+ T cells
expressing the OT-2 TCR transgene. Increasing concentrations
of IFN-a resulted in progressively reduced Th17 cell responses
in cultures containing Ifnar1+/+ DC, whereas addition of this cyto-
kine did not suppress the Th17 cell response in cultures contain-
ing Ifnar1/ DC (Figure 1D). These data suggest that constitu-
tive autocrine IFNAR signaling in DC is sufficient to suppress
Th17 cell responses. In sum, IFNAR on DC negatively regulates
Th17 cell responses upon antigen presentation to CD4+ T cells.
IFNAR Expression by DC Alters the Balance
between the Th17 Cell and Th1 Cell Response
We then asked whether the impact of Ifnar1/ DC on the IL-17
response reflected a generalized increase in potency of APC
activity. IFNAR deficiency did not alter expression of DC cell-sur-
face molecules involved in T cell activation including MHC class
I, class II, CD80, and CD40 (splenic DC, Figure S3A; BM-derived
DC, Figure S3B) and did not affect development of plasmacytoid
DC (pDC) or conventional DC (cDC) (data not shown). T cell pro-
liferation to antigen-pulsed Ifnar1/ and Ifnar1 WT DC was not
distinguishable under nonpolarized or two different Th17 cell-
polarizing conditions (rIL-23 and IL-4 + IFN-g Ab and rIL-6 +
rTGF-b) (Figure S3C). Although strong Th17 cell responses
were observed after stimulation of OT-2 T cells by Ifnar1/ DC
in cultures containing IL-6 and TGF-b (Figure 2A), T cell stimula-
tion under Th1 cell-polarizing conditions (IL-12 and IL-4 Ab) by
Ifnar1/ DC produced substantially weaker Th1 cell responses
compared to cultures containing Ifnar1+/+ DC (Figure 2B). These
findings indicate that enhanced induction of Th17 cell generation
by Ifnar1/ DC does not reflect a generalized increase in anti-
gen-presenting activity. Instead, Ifnar1/ DC acquire the ability
to skew T cells toward the Th17 cell pathway and away from Th1
cell development.
IFNAR-Dependent Regulation of Opn-i Expression
in DC and the Th17 Cell Response
Opn-deficient (Spp1/) mice develop milder EAE compared to
Opn-sufficient mice, and this has been attributed to expression
of Opn-s by activated T cells (Chabas et al., 2001; Jansson
et al., 2002; Shinohara et al., 2005, 2006; Hur et al., 2007). We
have defined a translational isoform of Opn that is expressed inImmunity 29, 68–78, July 18, 2008 ª2008 Elsevier Inc. 69
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IFNAR-Dependent Inhibition of Th17 Cell ResponsesFigure 1. IFNAR Signaling in DC Suppresses Th17 Cell Generation
(A) Polyclonal T cell activation. Top: CD4+ T cells (23 105 T cells/well) were incubated with soluble CD33Ab (1 mg/ml) and splenic DC for 5 days. CD4+ T cells were
then restimulated with CD33 Ab (1 mg/ml) for 24 hr. Intracellular cytokines were stained with PE-conjugated IL-17 Ab or biotin-conjugated IFN-g Ab followed by
CyChrome-conjugated streptavidin. Events of flow cytometry were gated on CD4+. DC were either unactivated or preactivated for 24 hr with LPS (1 mg/ml).
Bottom: Cell cultures were polarized to Th17 cells with rIL-23 and IFN-g + IL-4 Abs; data are representative of three experiments.
(B) Antigen-specific T cell activation of MOG-specific CD4+ T cells expressing the 2D2 TCR transgene. 2D2 T cells were activated by BM-derived DC (Ifnar1+/+
versus Ifnar1/) with 1 mg/ml of MOG peptide. Events of flow cytometry were gated on CD4+. Culture conditions were Th17 cell polarized with rIL-23 and with
IFN-g + IL-4 Ab. DC were pretreated with the indicated reagents for 4 hr. Data are representative of four experiments.
(C and D) CD4+ T cells expressing the OT-2 TCR transgenewere activated by BM-DC (Ifnar1+/+ versus Ifnar1/) and 1 mg/ml OT-2 peptide antigen. Cultures were
skewed to Th17 cells with rIL-6, rTGF-b, rIL-23, and IFN-g + IL-4 Abs (C), or not (D) with the indicated amounts of rIFN-a added to DC/T cell coculture. Data are
representative of five experiments. Culture supernatants were harvested 24 hr after T cell restimulation with soluble CD3 Ab and the amounts of IL-17 were
analyzed by ELISA in triplicate wells; shown as mean ± SEM.70 Immunity 29, 68–78, July 18, 2008 ª2008 Elsevier Inc.
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IFNAR-Dependent Inhibition of Th17 Cell Responsesthe cytosol of DC subsets, termed Opn-i (see above), so we
asked whether Opn-i expression by DC contributes to the devel-
opment of Th17 cells. IFNAR expression reduced the expression
of Opn-i in DC to 20%–25%, as judged by immunoblotting
(Figure 3A). Constitutive expression of IFNAR in the absence of
added ligand (recombinant) IFN-a inhibits Opn-i expression,
whereas addition of limiting concentrations of IFN (10 U/ml
of IFN-a or IFN-b) results in a further increase (up to 2-fold) in
suppression. Reduced Opn-i expression in Ifnar1+/+ DC was as-
sociated with reduced promotion of the Th17 cell response; ex-
pression of Opn by cDC, rather than pDC, was critical to Th17
cell generation (Figures 3B–3D). We also noted that Opn-defi-
cient T cells produced less IL-17 than OpnWT T cells, in cultures
containing Opn WT DC, opening the possibility that secreted
Opn (Opn-s) produced by activated T cells may augment the
Figure 2. IFNAR Expression by DC Alters the Balance between the
Th17 Cell and Th1 Cell Response
2D2 T cells were incubatedwith BM-derived DC and 1 mg/ml of OT-2 peptide in
cultures skewed to Th17 cells (rIL-6 and rTGF-b [A]) or Th1 cells (rIL-12 and
IL-4 Ab [B]). Supernatants harvested 24 hr after restimulation with soluble
CD3 Ab were analyzed by ELISA in triplicate wells shown asmean ± SEM; rep-
resentative of 5 and 3 experiments for (A) and (B), respectively.Th17 cell response, possibly via inhibition of T cell apoptosis,
as delineated by Hur et al. (2007) (Figure 3B). Opn-deficient
T cells were routinely used in these cocultures to study the iso-
lated Opn-dependent contribution of DC to the response (Fig-
ures 3C and 3D). Generation of Foxp3+ regulatory T cells (Treg)
was not affected by the amount of Opn expression in DC in the
absence of TGF-b (Figures 3C; Figure S4A), suggesting that
Opn-i expression in DC regulates Th17 cell generation without
affecting Treg production under these conditions. In addition,
Opn expression in DC did not alter the ability of T cells to prolif-
erate under IL-23-mediated Th17 cell-polarizing conditions
(Figure S4B). These findings indicate that IFNAR-dependent reg-
ulation of the Th17 cell response reflects inhibition of Opn-i ex-
pression in DC.
If suppression of Th17 cell development by IFNAR signaling
is mediated by inhibition of Opn-i expression, reconstitution of
Opn-i expression in Opn-deficient DC should restore Th17 cell
generation. We transduced Opn-deficient DC with a lentiviral
Opn-i vector, lenti-DOpn, which restores expression of intra-
cellular but not secreted Opn (Shinohara et al., 2006). Incubation
of T cellswith lenti-DOpn-transducedDCor lenti-GFP-transduced
Figure 3. IFNAR Signaling Suppresses Opn-i Expression and Th17
Cell Generation
(A) BM-derived DC cultured with Flt-3L were harvested on day 7 and replated
with or without IFN-a or rIFN-b (10 U/ml) as indicated. Opn-i was detected in
DC lysates by immunoblot and quantified by densitometry. The bar graph
summarizes the amounts of Opn normalized to actin; data are representative
of three experiments.
(B–D) CD4+ 2D2 Tg cells were stimulated by DC with 1 mg/ml MOG and rIL-23
and with IFN-g + IL-4 Abs.
(B) Supernatants of coculture including spleen-derived DC and 2D2 T cells
were harvested on day 6 after 24 hr of T cell restimulation with soluble CD3
Ab (1 mg/ml). The amount of IL-17 in supernatants was evaluated by ELISA
in triplicate wells. Shown are mean ± SEM and representative of seven
experiments.
(C) Opn-deficient (Spp1/) CD4+ 2D2 Tg T cells were incubated with BM-
derived DC and 1 mg/ml MOG peptide. Events of flow cytometry were gated
on CD4+. Representative of seven experiments.
(D) Total BM-DC were sorted by FACS into pDC and cDC. IL-17 levels in the
restimulated culture supernatants were determined by ELISA in triplicate wells
shown as mean ± SEM. Data are representative of four similar experiments.Immunity 29, 68–78, July 18, 2008 ª2008 Elsevier Inc. 71
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IFNAR-Dependent Inhibition of Th17 Cell ResponsesDC resulted in a 7-fold increase in the Th17 cell response and a
10-fold increase in IL-17 concentrations in culture supernatants.
However, IL-10 was not detectable in either culture supernatant,
and <1%of CD4+ T cells expressed intracellular IL-10 (Figure 4A;
Figure S5). These data suggested that IFNAR-dependent down-
regulation of Th17 cell development reflects inhibition of Opn-i
expression in DC.
In Vivo Th17 Cell Polarization Is Enhanced by Opn-i
Expression in Antigen-Presenting DC
To test this pathway in vivo, we evaluated the ability of Opn-de-
ficient and Opn-i-reconstituted DC to induce Th17 cell re-
sponses to the MOG peptide. Opn-deficient DC transduced
with lenti-Opn-i were pulsed with MOG peptide before injection
into Rag2/ mice along with naive 2D2 T cells (sorted as
CD4+CD62LhiCD44lo). One week later, the Th17 cell response
was defined immediately after harvesting cells from draining
LN after a 4 hr pulse with PMA and ionomycin before FACS anal-
ysis. In the absence of pertussis toxin, no sign of EAE onset was
observed in these mice. Immunization of mice with Opn-i-trans-
duced DC provoked a 2- to 3-fold increase in the Th17 cell re-
sponse compared with GFP-transduced Opn/ DC (Figure 4B).
Inhibition of Th17 Cell Differentiation by an IFNAR-Opn-i
Pathway Is Mediated by IL-27
IFNAR-dependent regulation of the Th17 cell response did not
reflect the impact of this receptor on cytokines that might require
Figure 4. Reconstitution of Opn-i Expression in Opn-Deficient DC
Rescues Th17 Cell Generation In Vitro and In Vivo
(A) BM-derived Opn-deficient DC transduced with lentivirus encoding either
Opn-i or GFP (negative control) were incubated with Opn-deficient CD4+
2D2 cells with 1 mg/ml MOG peptide under Th17 cell-polarizing conditions
(rIL-23, and IFN-g + IL-4 Abs). Cells were stained with IL-17 Ab on day 6
and supernatants harvested 24 hr after restimulation with CD3 Ab and ana-
lyzed by ELISA; representative of two experiments.
(B) Rag2/ hosts reconstituted i.v. with naive (CD44CD62L+) CD4+ 2D2 Tg
T cells (1.5 3 105/mouse) immunized by s.c. injection of MOG-pulsed BM-
DC (2 3 106/mouse). DLN cells harvested 7 days later were treated immedi-
ately with PMA and ionomycin for 4 hr followed by 2 hr of BFA treatment before
cell staining for FACS analysis. Dot plot shows IL-17 and IFN-g immuno-
fluorescence of DLN cells gated on CD4+. Numbers of DLN Th17 cells per
mouse (n = 3) calculated from total numbers of DLN cells and proportions of
CD4+IL-17+ double-positive cells. Error bars represent mean ± SD.72 Immunity 29, 68–78, July 18, 2008 ª2008 Elsevier Inc.the Th17 cell response, including IL-6, TGF-b, IL-23, and IFN-g
(Figures 1A–1C, 2A, 2B, 3B–3D, and 4A). Because expression
and secretion of IL-27 by DC can exert potent suppressive
effects on Th17 cell generation (Batten et al., 2006; Stumhofer
et al., 2006), we asked whether IFNAR-mediated inhibitory path-
way depicted in Figure S6A resulted in increased IL-27 expres-
sion. Activation of Ifnar1+/+ but not Ifnar1/ DC by LPS resulted
in progressively increasing concentrations of IL-27 (Figure 5A).
Addition of limiting concentrations of IFN-a to Opn-deficient
DCdid not further enhance IL-27 responses. In contrast, addition
of the same concentrations of IFN-a to Opn WT DC resulted in
a dose-dependent induction in IL-27 secretion (Figure 5B, right),
suggesting that Opn-i inhibition is a key element in enhanced
IL-27 expression under these conditions. High concentration
of DC without stimulation showed that IL-27 is induced by
IFNAR expression and absence of Opn (Figure 5C, left and
middle). Lentiviral expression of Opn-i confirmed that Opn-i pro-
motes secretion of IL-27 in unstimulated DC (Figure 5C, right).
Induction of IL-27p28 mRNA expression was also confirmed
by quantitative PCR in IFNAR-deficient and Opn-sufficient DC
(Figure 5D).
Todirectly test thehypothesis that the IFNAR-Opn-i axis result-
ing in enhanced expression of IL-27was responsible for suppres-
sion of Th17 cell responses, we measured the effects of neutral-
izing IL-27 antibody in these cultures. Addition of IL-27
neutralizing antibody to cultures containing Opn-deficient unsti-
mulatedDC, under two different Th17 cell-polarizing culture con-
ditions, successfully restored the Th17 cell response (Figure 5E),
i.e., reversed suppression of the Th17 cell response in cultures
containing Opn-deficient DC. In contrast, treatment of cultures
containingOpnWTDCwith IL-27 neutralizing antibody hadnoef-
fect on the Th17 cell response in these cultures (Figure S6B).
Moreover, addition of IL-27 antibody to cultures containing IFN-a
also restored the Th17 cell response (Figure 5F). These findings
indicated that IFNAR-dependent suppression of Th17 cell
responses is mediated by enhanced secretion of the inhibitory
IL-27 cytokine.
Delayed EAE Onset in Opn-Deficient Hosts Associated
with Increased IL-27 Expression and Altered Ratio
of Th1 and Th17 Autoreactive Cells
These analyses suggested that promotion of Th17 cell re-
sponses by DC requires expression of Opn-i in these APC. Early
experiments of Langrish et al. (2005) showed that IL-17 is essen-
tial to the development of severe EAE. We therefore investigated
whether presentation of autoantigen by Opn-deficient APC
might impair development of EAE. Opn-deficient Rag2/ hosts
reconstituted with naive (CD4+CD62LhiCD44lo) MOG-specific
2D2 T cells displayed a substantially delayed onset of EAE com-
pared to Opn WT Rag2/ hosts (Figure 6A) characterized by
delayed lymphocyte and macrophage infiltration into spinal
cord (Figure 6B). We also analyzed mice on days 12 (Opn WT)
and 17 (Opn-deficient) in a separate experiment from Figure 6A
when OpnWT and Opn-deficient hosts displayed a clinical score
of 3–3.5 for analysis of serum IL-27. Serum IL-27 concentrations
of Opn WT hosts were 5–10 pg at day 5 and 17, whereas serum
IL-27 amounts in Opn-deficient hosts were 40 pg/ml at day 5 and
80 pg/ml at day 17 (Figure 6C). Splenic DC from Opn-deficient
Rag2/ hosts also expressed higher amounts of IL-27p28
Immunity
IFNAR-Dependent Inhibition of Th17 Cell ResponsesFigure 5. Suppression of IL-27 Expression in DC Contributes to
Opn-i-Mediated Th17 Cell Differentiation
(A) BM-derived DC (Ifnar1+/+ [closed circle] versus Ifnar1/ [open circle]) were
incubated (2 3 106 DC/ml) with the indicated concentration of LPS for 30 hr.
Supernatants were evaluated for IL-27p28 amounts by ELISA in triplicate
well; representative of three experiments.
(B) BM-derived DC (Spp1 WT [closed circle] versus Spp1/ [open circle])
were incubated with rIFN-a (5 3 106 DC/ml) for 42 hr. IL-27p28 amounts
were determined. Representative of two experiments.
(C) Resting BM-derived DC were incubated for 48 hr. IL-27p28 amounts were
determined by ELISA in triplicate wells. Left: Comparison of IL-27 secretion by
Ifnar1+/+ and Ifnar1/ DC (107 DC/ml) in 44 hr culture supernatants. Middle:
Comparison of IL-27 secretion by Opn WT and Opn-deficient (Spp1/) DC
(2 3 106 DC/ml) in 44 hr culture supernatants. Right: Comparison of IL-27
secretion by Opn-deficient DC transduced with lenti-GFP (control) or lenti-
DOpn-i (2 3 106 DC/ml) in 24 hr culture supernatants; data representative of
two experiments.
(D) Comparison of the amounts of IL-27p28 mRNA in resting BM-derived
DC from Ifnar1+/+ or Ifnar1/ mice Real-time PCR of total cDNA andthan DC from Opn WT Rag2/ hosts (Figure S7), and brains
of Opn-deficient hosts expressed 10-fold higher IL-27p28
mRNA amounts than Opn WT hosts (data not shown).
Increased amount of serum IL-27 in Opn-deficient hosts be-
ginning at day 5 (Figure 6C) was associated with substantially
reduced Th17 cell responses in draining LN—2.54% (Opn-defi-
cient) versus 17.6% (Opn WT) Th17 cells (Figure 6D). Analysis
of the spinal cord and brain later in the course of EAE in
Opn-deficient hosts revealed a 2-fold increase in the proportions
of Th1 cells (20% to 48%) and a doubling of CD4+ T cells (ap-
proximately 9 3 105 to 2.1 3 105), representing a 4-fold enrich-
ment of the CNS Th1 cell response in Opn-deficient hosts
(Figure 6E). This is consistent with findings that IL-27 can
enhance Th1 cell responses in other settings (Pflanz et al.,
2002; Cao et al., 2008) and suggests that suppression of the
Th17 cell response in Opn-deficient Rag2/ hosts is apparent
before onset of disease.
Opn Expression in Microglia Is Essential for Th17
Cell-Mediated Progression of EAE
Because restimulation of T cells by APC in CNS is necessary for
full development of EAE (Tompkins et al., 2002; Kawakami et al.,
2004), we asked whether microglia also required expression
of Opn-i to induce Th17 cell responses to MOG peptide
(Figure 7A). Lentiviral-mediated reconstitution of Opn-deficient
microglia with Opn-i resulted in substantially increased pro-
duction of IL-17 and decreased production of IL-27p28
(Figure 7B).
To test the contribution of Opn expression by CNS-resident
microglia to EAE, we induced EAE in irradiation BM chimeras,
in which host (radiation-resistant) microglia were Opn WT or
Opn deficient whereas peripheral hematopoietic APC were de-
rived from donor (Spp1/) BM cells (Greter et al., 2005; Heppner
et al., 2005). Opn deficiency in the CNS compartment dramati-
cally reduced the intensity of EAE in radiation chimeras in which
the hematopoietic compartment of Opn-deficient or Opn WT
hosts was reconstituted with 1.7 3 107 Opn-deficient BM cells
(Figure 7C), suggesting that expression of Opn in microglia is
necessary for efficient development of EAE. These findings
may also be relevant to MS pathogenesis, because overexpres-
sion of Opn in MS plaques is a notable feature of active disease
(Steinman and Zamvil, 2003).
results obtained from cycling threshold (DDCt) values normalized to
b-actin.
(E and F) Two different Th17 cell skewing conditions were tested. Top: rIL-
23 and IFN-g + IL-4 Abs; bottom: rIL-6 and rTGF-b.
(E) 2D2 T cells were incubated with Opn-deficient BM-DC, 1 mg/ml MOG
peptide, and 20 mg/ml IL-27 Ab or isotype IgG. 24 hr after T cell restimu-
lation with soluble CD3 Ab on day 5, expression of IL-17 and IFN-g was
evaluated by flow cytometry (events gated on CD4+). The amount of IL-
17 in culture supernatants was measured by ELISA in triplicated wells
(mean ± SEM). Representative of four experiments.
(F) DC and OT-2 T cell cocultures under the same skewing conditions
used in (E) were treated with rIFN-a with or without IL-27 Ab (20 mg/ml)
and stimulated with OVA peptide for 5 days, followed by 24 hr T cell re-
stimulation with soluble CD3 Ab. Expression of IL-17 and IFN-g was eval-
uated by flow cytometry (events gated on CD4+). The amount of IL-17 in
culture supernatants was analyzed by ELISA in triplicate wells is shown
(mean ± SEM); data are representative of two experiments.Immunity 29, 68–78, July 18, 2008 ª2008 Elsevier Inc. 73
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IFNAR-Dependent Inhibition of Th17 Cell ResponsesFigure 6. Opn Deficiency in Non-T Cells Delays EAE Onset
(A) EAE development in Rag2/ hosts. Naive CD4+ 2D2 Tg Opn-deficient T cells (1.4 3 105 cells/mouse) were adoptively transferred into Opn WT or Opn-de-
ficient Rag2/ hosts. Disease development and incidence are shown for each group. OpnWT, closed circle, n = 9; Spp1/, open circle, n = 8; error bars denote
mean ± SEM. Data are representative of three experiments.
(B–E) Analysis of mice at different time points in separate experiments.
(B) CD4+ 2D2 T cells from B6 2D2 Tgmice were adoptively transferred to either OpnWT or Opn-deficient B6Rag2/mice, as described in (A). Twenty days later,
the total number of spinal-cord-infiltrated cells, spinal-cord-infiltrated macrophages (%) (F4/80+CD45hi), and total CD4+ T cells were enumerated. Increased lym-
phocyte infiltration was observed in Opn WT hosts (closed circle) compared with Opn-deficient (open circle) hosts. Negative control (asterisk) mice are Rag2/
micewithout T cell transfer. Average disease scores of the OpnWT andOpn-deficient (Spp1/) hosts used for these experiments (at day 20) were 3.8 and 1.2 for
Opn WT and Opn-deficient hosts, respectively. Horizontal lines denote mean values.
(C) Serum IL-27 analysis. Rag2/ hosts were analyzed when EAE scores were either 0 (day 5) or 3–3.5 (day 12 and day 17 for Opn WT and Opn-deficient hosts,
respectively). Error bars represent mean ± SD from values of 3 mice (score 0) or 4 mice (score 3–3.5) each of Opn WT and Opn-deficient Rag2/ hosts.
(D) Th17 and Th1 cell development. Cells fromDLNwere harvested frommice on day 5 (score = 0), treated immediately with PMA and ionomycin followed by BFA
treatment, and subject to FACS analysis; dot plots were gated on CD4+ cells.
(E) Th cell subsets in CNS. Cells from spinal cord or brain were harvested from score 3–3.5mice on day 12 and 17 fromOpnWT andOpn-deficientRag2/ hosts,
respectively, treated immediately as described in (D). Panels represent results of 3 mice (score 0) or 4 mice (score 3–3.5) each from Opn WT and Opn-deficient
Rag2/ hosts.DISCUSSION
It has taken two to three decades after the original description of
Th1 and Th2 cells for Th17 cells to be identified as a new lineage
of effector CD4+ T cells. This delayed recognition reflects, in part,
the relative paucity of Th17 cells after conventional immunization
with antigen. In the absence of a cytokine milieu required to in-
duce and expand Th17 cell development, stimulation of T cells
from antigen-immunized mice often generates less than 1%
Th17 cells, compared to much higher proportions of Th1 cells
(Park et al., 2005; Gocke et al., 2007). Because generation of
murine Th17 cells fromnaive cells requires IL-6, TGF-b (Veldhoen
et al., 2006; Bettelli et al., 2006), and IL-23 for Th17 cell expan-
sion (Park et al., 2005; Harrington et al., 2005), a relative insuffi-74 Immunity 29, 68–78, July 18, 2008 ª2008 Elsevier Inc.ciency of these cytokines may dampen the Th17 cell response.
However, a more efficient mechanism responsible for pre-emp-
tion of Th17 cell responses probably depends on the IFNAR-
dependent inhibitory pathway described in this report.
The negative impact of IFNAR engagement on Th17 cell
responses was mediated through inhibition of Opn-i expression,
which in turn enhanced IL-27-dependent inhibition of Th17 cell
development. We have not ruled out the possibility that IFNAR
signaling in T cells may also inhibit expansion or survival
of Th17 cells. Although extremely low amounts of IFN-I were suf-
ficient to effectively initiate this IFNAR-dependent pathway in DC
and attenuate Th17 cell development, increasing amounts of
IFN-I, e.g., after certain viral infections, may be necessary to fully
inhibit Th17 cell responses. According to this view, IFN-I
Immunity
IFNAR-Dependent Inhibition of Th17 Cell Responsesconstitutively produced at low amounts in the absence of viral in-
fection may chronically dampen Th17 cell responses, whereas
increased IFNAR signaling secondary to rapid increases in
IFN-I amounts after viral infections may be necessary for in-
creased IL-27-dependent inhibition of Th17 cell responses. In
contrast, certain bacterial or fungal infections that disrupt this in-
hibitory pathway may provoke robust Th17 cell responses and
increase the risk of autoimmune disease. It may be relevant
that Th17 cell generation is also suppressed by expression of
the IFN-g receptor on APC (Batten et al., 2006), and the potential
similarities between IFN-a- and IFN-g-dependent suppression
of the Th17 cell response via interactions with DC deserve further
investigation.
IL-27, a potent inhibitor of Th17 cell development, can also in-
duce IL-10-producing T cells (Awasthi et al., 2007; Fitzgerald
et al., 2007). Our DC-T cell cocultures do not produce sufficiently
high IL-27 concentrations to enhance IL-10-producing cells,
suggesting that inhibition of Th17 cell responses that we observe
does not reflect enhanced production of IL-10. Huber et al.
(2008) have shown that IL-27, in addition to being a potent inhib-
itor of Th17 cell development (Stumhofer et al., 2006), also
Figure 7. Microglia Require Opn-i Expression to Induce Th17 Cells
Opn-deficient microglia were infected with lenti-Opn-i or lenti-GFP and
incubated 2D2+CD4 T cells and MOG peptide.
(A and B) Reconstitution of Opn-deficient microglia with Opn-i rescues IL-17
production by CD4+ 2D2 T cells.
(A) IL-17 concentrations in culture supernatants 24 hr after T cell restimulation
on day 4 were determined by ELISA in triplicate wells.
(B) Concentrations of IL-27p28 in day 4 cultures before T cell restimulation. The
amounts of IL-27p28 were determined by ELISA in triplicate wells; empty and
filled bars denote supernatants from Opn-i-transfected and GFP-transfected
DC, respectively, and data are representative of two experiments.
(C) EAE development is inhibited in irradiated Opn-deficient hosts. Total BM
cells (1.73 107 cells/mouse) from 2D2+ Tg Opn-deficient mice were i.v. trans-
ferred to irradiated (800 rads) hosts. Ten weeks later, EAE was induced.
Disease development (mean clinical score) and incidence (%) is shown for
each group (n = 5). Error bars in disease score denote mean ± SEM and
t test values on the last day of observation are shown. Mice displayed >95%
engraftment of donor bone marrow according to immunofluorescence with
Ly5.2 Ab (donor BM cells were obtained from B6.Ly5.2+ Opn-deficient mice
expressing the 2D2 TCR transgene) 10 weeks after reconstitution and before
disease induction, as judged by immunofluorescence of peripheral blood cells.inhibits TGF-b-mediated expansion of Treg cells. Low concen-
trations of IL-27 sufficient to suppress Th17 cell responses in cul-
tures containing Opn-deficient DC did not substantially alter
TGF-b-dependent generation of Foxp3+ Treg cells in this study,
a finding that emphasizes the striking susceptibility of the Th17
cell response to low concentrations of IL-27 and also indicates
that Treg cell induction is not required to inhibit the Th17 cell
response in our experiments.
Previous studies have indicated that Opn-i expression in pDC
promotes expression of IFN-a and contributes to early protective
responses against HSV-1 infection and tumor growth (Shinohara
et al., 2006). Here, we show that Opn-i expression by conven-
tional DC (cDC) (and microglia) contributes to Th17 cell commit-
ment in vitro and in vivo in the setting of EAE. Opn expression is
induced after TLR9 engagement of pDC but not cDC (Shinohara
et al., 2006), so Th17 cell generation may be negatively regulated
by pDC-dependent production of IFN-a through engagement of
IFNAR expressed by cDC. Additional experiments are necessary
to evaluate the contribution of an inhibitory interaction between
DC subsets: IFN-I-producing pDC (which do not themselves pro-
mote detectable Th17 cell responses) and IFNAR-producing
cDC in regulating the Th17 cell response.
Opn (Spp1) gene expression in T cells is essential for efficient
Th1 cell development (Ashkar et al., 2000; O’Regan et al., 2000;
Chabas et al., 2001; Shinohara et al., 2005; Sato et al., 2005;
Renkl et al., 2005), whereas expression in cDC promotes Th17
cell differentiation. The contribution of Opn to the development
of these Th cell lineages reflects cell-type-specific expression
of the two Opn isoforms. Secretion of Opn (Opn-s) by T cells
leads to an interaction with its receptors on macrophages that
upregulates IL-12 production and enhances Th1 cell develop-
ment. In addition, Opn-deficient T cells produced less IL-17
than did Opn WT T cells in cultures containing Opn WT DC, sug-
gesting that secreted Opn (Opn-s) may also augment the Th17
cell response under some circumstances, possibly through a di-
rect interaction that inhibits apoptosis (Hur et al., 2007). In addi-
tion to inhibition of IL-27, Opn-i may also promote Th17 cell
responses through enhancement of DC-T cell interactions.
Opn-i-dependent polarization of the actin cytoskeleton may
enhance formation of immunological synapses necessary for
efficient T cell activation and helper lineage commitment (Al
Alwan et al., 2003; Shapiro et al., 2003; Benvenuti et al.,
2004a, 2004b; Maldonado et al., 2004; West et al., 2004).
We tested two different models of EAE: (1) naive 2D2 CD4+
T cell transferred into Rag2/ hosts and (2) irradiation BM chi-
mera reconstituted with 2D2 BM cells (in both models, trans-
ferred cells were Opn deficient to rule out excess Opn-s). EAE
development was robust in the former system, characterized
by efficient T cell activation and infiltration into the CNS (data
not shown), allowing us to examine full-blown EAE in Opn-defi-
cient mice. This model also allowed analysis of the role of Opn
in APC and revealed that Opn-deficient APC promoted a domi-
nant Th1 cell type of EAE. Enhanced Th1 cell responses in
the CNS of Opn-deficient Rag2/ hosts were associated with
increased IL-27 secretion by DC and/or microglia, which may
have resulted in enhanced IFN-g responses (Pflanz et al.,
2002; Cao et al., 2008). Analyses of Th17 and Th1 cell compo-
nents of CNS cellular infiltrates at different stages of EAE
induced by different autoantigens may define clinically distinctImmunity 29, 68–78, July 18, 2008 ª2008 Elsevier Inc. 75
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clinical subtypes of MS.
Definition of the IFNAR signaling pathway in DC leading to
suppression of Th17 cell responses described in this report pro-
vides insight into the essential elements that govern the Th17 cell
response. In addition, these findings are relevant to the use of
IFN-b as the leading treatment for patients suffering from MS
(Paty et al., 1993; Hafler et al., 2005). The ability of IFN-b, an
innate immune cytokine with antiviral properties, to inhibit auto-
immune inflammation and reduce the incidence of disease
relapse has been poorly understood. Suppression of the devel-
opment of proinflammatory Th17 cells provides a mechanistic
explanation for the therapeutic effects of type I interferon therapy
in MS. These findings also suggest that analysis of the effects of
IFNAR engagement by antibodies or mutant IFNs that differen-
tially engage the Opn-IL-27 pathway described here may yield
new and effective therapies for MS.
EXPERIMENTAL PROCEDURES
Animals and Reagents
Opn-deficient (Spp1/) mice (Rittling et al., 1998) were backcrossed to
C57BL/6 (B6) for 15 generations; B6 2D2 MOG-specific T cell receptor trans-
genic mice (Bettelli et al., 2003) were a gift from V.K. Kuchroo (Brigham and
Women’s Hospital, Boston, MA). B6 OT-2 TCR transgenic mice and B6
Ly5.2 mice (Jackson Labs, Bar Harbor, ME) and 129/SvEv IFNAR1-deficient
mice (B&K Universal, Hull, England) were used. Antibodies to IL-17 (TC11-
18H10) and IFN-g (XMG1.2) for flow cytometry were from BD PharMingen;
Foxp3 (FJK-16 s) and IL-10 (JES5-16E3) Abs were from eBioscience;
IL-27p28 Ab (BAF1834), recombinant proteins for mouse IL-23, IL-6, Flt-3L,
and human TGF-b1 were from R&D systems; and recombinant mouse
IFN-awas from HyCult. Lentiviral constructs ofOpnwithout the signal peptide
(DOpn) were as described (Shinohara et al., 2006). MOG35-55 peptide (MEVG
WYRSPFSRVVHLYRNGK) and OVA329-339 peptide (ISQAVHAAHAEINEAGR)
were from New England Peptides. All work involving vertebrate animals was
reviewed and approved by the DFCI IACUC and conducted in accordance
with AAALAC guidelines.
EAE Induction
Induction was performed as described (Shinohara et al., 2005) with MOG pep-
tide in CFA s.c. on day 0 and pertussis toxin i.v. on days 0 and 2. Mice were
assessed daily for clinical signs of disease in a blinded fashion and graded
as described previously. Mean clinical scores and mean maximal scores
were recorded daily and calculated by adding scores of individual mice and di-
viding by number of mice in each group, includingmice with no sign of disease.
Preparation of CD4+ T Cells, DC, Microglia,
and Spinal Cord Lymphocytes
Performed as described previously (Shinohara et al., 2006). Naive T cells were
FACS sorted as CD4+CD62LhiCD44lo and splenic DC were derived after colla-
genase treatment and positive selection with CD11c MACS beads (Miltenyi).
BM-derived DC were prepared according to an in vitro culture method (Gilliet
and Liu, 2002) with modifications (Shinohara et al., 2006), whereas further
purification of pDC and cDC is described in Shinohara et al. (2006). Primary
microglia were prepared as previously described (Dalpke et al., 2002), result-
ing in >98% Mac-1+F4/80+ cells. To prepare lymphocytes from spinal cord,
single cells were prepared by Percoll spin after collagenase treatment of spinal
cord.
APC-T Cell Coculture
13 105 DC/well and 23 105 CD4+ T cells/well were incubated in 200 ml/well of
complete RPMI media with antigen or soluble CD33 Ab (BD PharMingen). For
microglia-T cell cocultures, 2.5 3 105/well each of microglia and 2D2 T cells
were incubated in 500 ml/well with RPMI media. Th17 cell polarization entailed
rIL-23 (100 ng/ml) and IFN-g + IL-4 Ab (10 mg/ml each) or rIL-6 (20 ng/ml) and76 Immunity 29, 68–78, July 18, 2008 ª2008 Elsevier Inc.rTGF-b (3 ng/ml) at culture initiation. Culture supernatants in Figure 1C in-
cluded rIL-23 (10 ng/ml), rIL-6 (20 ng/ml), rTGF-b (1 ng/ml), and IFN-g + IL-4
antibodies (10 mg/ml each). In some experiments, IL-27 was neutralized with
IL-27 Ab (20 mg/ml). For Th1 cell polarization, rIL-12 (5 ng/ml) and IL-4 Ab
(10 mg/ml) were added during set up of cocultures.
Irradiation BM Chimeric Mice
B6OpnWT and deficientmicewere irradiated (800 rads) 24 hr before i.v. trans-
fer of total BM cells from Opn-deficient 2D2 mice (1.73 107 cells/mouse). Ten
weeks later, EAE was induced as indicated above.
In Vivo Development of Th17 Cells
B6 Rag2/ mice were transferred i.v. with Opn-deficient naive 2D2 CD4+
T cells (1.5 3 105/mouse; CD4+CD62LhiCD44lo). BM-derived DC (infected by
lentivirus, below) were pulsed with 20 mg/ml of MOG for 3 hr at 37C and
then extensively washed. Mice were immunized with 2 3 106/mouse of
MOG-pulsed DC by s.c. injection. Draining LN cells were excised 7 days later
and treated with PMA and ionomycin (4 hr) and brefeldin A (in the last 2 hr)
before FACS analysis.
Lentiviral Opn-i Transfection
Opn-i and GFP constructs were lentivirally transfected into DC or microglia as
described (Shinohara et al., 2006).
ELISA and Intracellular Cytokine Flow Cytometry
After antigen-specific stimulation with DC for 5–6 days, T cells were restimu-
lated for 24 hr with soluble CD33Ab (145-2C11, BDPharMingen) before culture
supernatants were analyzed for IL-17 and IL-27p28 concentrations by ELISA
(R&D Systems). Intracellular cytokine and Foxp3 staining was performed on
cells treated with ionomycin (500 ng/ml) and PMA (50 ng/ml) for 4 hr and bre-
feldin A (10 mg/ml) for the last 2 hr. Cells were stained for cell-surface markers,
fixed and permeabilized with Fix/Perm solution (eBioscience), followed by
FcBlock (2.4G2, BD PharMingen) and intracellular staining. Gating of intra-
cellular cytokine staining was determined by immunofluorescence with an
isotype-matched control Ig (Ab control) and, in some experiments, immunoflu-
orescence of an (IL-17) CD8+ T cell line with IL-17 Ab (cell control) was used
as well.
Immunoblotting of DC Lysates
BM-derived DC were prepared as described above. On day 7 of culture,
DC were harvested and cell lysates were either immediately prepared (0 hr
samples) or prepared 12 hr after replating cells in RPMI complete medium
with or without recombinant IFN-a or IFN-b (12 hr samples). 10 mg/lane
of DC lysate was applied to an SDS-PAGE gel and proteins were blotted
onto a PDVF membrane before immunodetection was performed with Opn
Ab (O-17, IBL, America).
RNA-cDNA Preparation and Real-Time PCR
After washing DC with PBS, total RNA was extracted from cells with an
RNeasy kit (QIAGEN). cDNA synthesis was initiated by priming total RNA
with oligo (dT) before RNA was reverse-transcribed with MMLV RT (Ambion).
The resultant cDNAwas used for real-time PCR analyses with an ABI 7700 (Ap-
plied Biosystems). QuantiTect SYBRGreen PCR (QIAGEN) was used to detect
IL-27p28, and b-actin was used as an internal control. (IL-27p28 forward: 50-
CTC TGC TTC CTC GCT ACC AC-30, reverse; 50-GGG GCA GCT TCT TTT
CTT CT-30; b-actin primers forward: 50-TGT TAC CAA CTG GGA CGA CA-30,
reverse; 50-CTG GGT CAT CTT TTC ACG GT-30 ). Error bars indicate the max-
imum and minimum values calculated from SD and -DDCt values from tripli-
cate PCR reactions, according to Applied Biosystems protocols.
SUPPLEMENTAL DATA
Supplemental Data include seven figures and can be found with this article
online at http://www.immunity.com/cgi/content/full/29/1/68/DC1/.
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